The Emerging Role for CTL Epitope Specificity in HIV Cure Efforts

J Infect Dis. 2021 Feb 15;223(12 Suppl 2):32-37. doi: 10.1093/infdis/jiaa333.

Abstract

The development of an effective human immunodeficiency virus (HIV) cure is a critical global health priority. A major obstacle to this effort is the establishment of a latent reservoir of HIV infected cells, which necessitates lifelong therapy, causing both logistical and adherence burdens for infected individuals. However, in a subset of these individuals, cytotoxic T lymphocytes (CTLs) can durably suppress viral outgrowth in the absence of therapy, providing a path towards a viable HIV cure. In this review, we discuss the emerging role that CTLs have in HIV cure efforts, with particular emphasis on epitope specificity. Recent studies have demonstrated that successful in vivo containment of the virus is rooted in the specific targeting of fitness-constrained, mutation-resistant regions of the HIV proteome. We highlight these new insights, providing context with previous observations in HIV and other models of viral control, and delineate their translation into a therapeutic vaccine.

Keywords: CTL; HIV; cure; epitope; network; vaccine.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS Vaccines / genetics
  • AIDS Vaccines / immunology
  • Animals
  • Epitopes, T-Lymphocyte / genetics
  • Epitopes, T-Lymphocyte / immunology*
  • HIV Infections / immunology*
  • HIV Infections / therapy
  • HIV Infections / virology
  • HIV-1 / genetics
  • HIV-1 / physiology*
  • Humans
  • T-Lymphocytes, Cytotoxic / immunology*

Substances

  • AIDS Vaccines
  • Epitopes, T-Lymphocyte